# Empagliflozin in Adolescent Diabetes

> **NCT04917692** · PHASE4 · WITHDRAWN · sponsor: **Ohio State University**

## Conditions studied

- type1diabetes

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT04917692
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07
- **Primary completion:** 2022-06
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not funded
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917692, "Empagliflozin in Adolescent Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04917692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*